- Home
- FUSB vs RFL Comparison
FUSB vs RFL Comparison
Compare FUSB & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FUSB | RFL |
|---|---|---|
| Founded | 1952 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Real Estate |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.1M | 92.6M |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | FUSB | RFL |
|---|---|---|
| Price | $16.50 | $2.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.0K | ★ 307.5K |
| Earning Date | 04-29-2026 | 06-10-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ 28.28 |
| EPS | ★ 0.33 | N/A |
| Revenue | N/A | ★ $917,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $50.71 | ★ N/A |
| Revenue Growth | N/A | ★ 43.96 |
| 52 Week Low | $10.47 | $1.12 |
| 52 Week High | $16.99 | $3.96 |
Technical Indicators
Market Signals| Indicator | FUSB | RFL |
|---|---|---|
| Relative Strength Index (RSI) | 49.42 | 43.94 |
| Support Level | $15.75 | $1.21 |
| Resistance Level | $16.50 | $3.96 |
| Average True Range (ATR) | 0.24 | 0.37 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 0.00 | 0.47 |
Price Performance
Historical ComparisonAbout FUSB First US Bancshares Inc.
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement accounts, and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.